Literature DB >> 16249702

Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.

David M Moore1, Robert S Hogg, Benita Yip, Evan Wood, Mark Tyndall, Paula Braitstein, Julio S G Montaner.   

Abstract

OBJECTIVE: To examine the independent association of discordant virologic and immunologic responses to highly active antiretroviral therapy (HAART) with mortality.
METHODS: A population-based study of 1527 treatment-naive individuals initiating HAART used Cox proportional hazards modeling to determine the independent association of treatment response at 3 to 9 months with nonaccidental mortality. Logistic regression was used to examine associations with discordant responses.
RESULTS: Viral load (VL)/CD4 discordant responses were seen in 235 (15.4%) of subjects, and VL/CD4 responses were seen in 179 (11.7%) of subjects. In adjusted Cox regression models, discordant responses were found to be independently associated with an increased risk of mortality (VL/CD4: relative hazard [RH] = 1.87, 95% confidence interval [CI]: 1.15 to 3.04; VL/CD4: RH = 2.47, 95% CI: 1.54 to 3.95). VL/CD4 discordance was found to be associated with increasing age, baseline HIV RNA load <100,000 copies/mL, baseline CD4 counts <50 cells/muL, the use of lamivudine (3TC)/zidovudine (ZDV), and poor adherence to therapy. VL/CD4 discordance was associated with younger age; injection drug use; baseline HIV RNA load >100,000 copies/mL; the use of 3TC/ZDV, didanosine (ddI)/3TC, or ddI/stavudine; and poor adherence to therapy.
CONCLUSION: Discordant responses are independently associated with an increased risk of mortality and are, in turn, associated with poor adherence to therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249702     DOI: 10.1097/01.qai.0000182847.38098.d1

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  66 in total

1.  Randomized, controlled clinical trial of zinc supplementation to prevent immunological failure in HIV-infected adults.

Authors:  Marianna K Baum; Shenghan Lai; Sabrina Sales; J Bryan Page; Adriana Campa
Journal:  Clin Infect Dis       Date:  2010-06-15       Impact factor: 9.079

2.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings.

Authors:  Rami Kantor; Lameck Diero; Allison Delong; Lydia Kamle; Sarah Muyonga; Fidelis Mambo; Eunice Walumbe; Wilfred Emonyi; Philip Chan; E Jane Carter; Joseph Hogan; Nathan Buziba
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

3.  Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

Authors:  Paul Krogstad; Kunjal Patel; Brad Karalius; Rohan Hazra; Mark J Abzug; James Oleske; George R Seage; Paige L Williams; William Borkowsky; Andrew Wiznia; Jorge Pinto; Russell B Van Dyke
Journal:  AIDS       Date:  2015-03-27       Impact factor: 4.177

4.  Simultaneous determination of antiretroviral drugs in human hair with liquid chromatography-electrospray ionization-tandem mass spectrometry.

Authors:  Yan Wu; Jin Yang; Cailing Duan; Liuxi Chu; Shenghuo Chen; Shan Qiao; Xiaoming Li; Huihua Deng
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2018-03-11       Impact factor: 3.205

5.  Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Authors:  Matthew Bidwell Goetz; Monique R Ferguson; Xueliang Han; Greg McMillan; Marty St Clair; Keith A Pappa; Daniel R McClernon; William A O'Brien
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

6.  Treating HIV-1 Infection: What Might the Future Hold?

Authors:  Mathias Lichterfeld; Kimon C Zachary
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

7.  Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China.

Authors:  Ye Ma; Decai Zhao; Lan Yu; Marc Bulterys; Matthew L Robinson; Yan Zhao; Zhihui Dou; Philippe Chiliade; Xiaoyu Wei; Fujie Zhang
Journal:  Clin Infect Dis       Date:  2010-01-15       Impact factor: 9.079

8.  Anthropometric and immunological success of antiretroviral therapy and prediction of virological success in west African adults.

Authors:  Eugène Messou; Delphine Gabillard; Raoul Moh; André Inwoley; Souleymane Sorho; Serge Eholié; François Rouet; Catherine Seyler; Christine Danel; Xavier Anglaret
Journal:  Bull World Health Organ       Date:  2008-06       Impact factor: 9.408

9.  An alternative methodology for the prediction of adherence to anti HIV treatment.

Authors:  I Richard Thompson; Penelope Bidgood; Andrea Petróczi; James C W Denholm-Price; Mark D Fielder
Journal:  AIDS Res Ther       Date:  2009-06-01       Impact factor: 2.250

10.  Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance.

Authors:  Damalie Nakanjako; Agnes Kiragga; Fowzia Ibrahim; Barbara Castelnuovo; Moses R Kamya; Philippa J Easterbrook
Journal:  AIDS Res Ther       Date:  2008-10-28       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.